Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6291-6300
DOI: 10.1111/dom.70812 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 05.05.2026. Verfasst von Takeshi Miyatsuka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Metabolism, Kitasato University School of Medicine, Sagamihara, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists, Drug Monitoring. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To investigate adherence to and persistence with free combination therapy (daily basal insulin plus an injectable glucagon‐like peptide‐1 receptor agonist [GLP‐1 RA]) versus fixed‐ratio combination (FRC) therapy (basal insulin plus a GLP‐1 RA) among individuals with type 2 diabetes (T2D) in Japan. Materials and Methods This retrospective, observational cohort study used DeSC‐IQVIA Integrated claims data from Japan to identify adults (aged ≥ 18 years) with confirmed T2D and ≥ 1 prescription for a GLP‐1 RA (with predefined basal insulin persistence window) or an FRC during October 2019 to September 2023. Study index was date of first GLP‐1 RA or FRC prescription; follow‐up was 365 days. The primary objective was to evaluate adherence to and persistence with free combination therapy versus FRC therapy.
Results
Age (mean [standard deviation]) at index was statistically significantly higher in the free combination group (67.0 [13.85] years, n = 2063) than in the FRC group (65.7 [13.85] years, n = 2386) ( p = 0.002). Odds of optimal adherence at end of follow‐up were statistically significantly higher with FRC therapy than with free combination therapy (adjusted odds ratio [95% confidence interval]: 1.96 [1.73–2.23]; p < 0.001). Risk of discontinuation by end of follow‐up was statistically significantly lower with FRC therapy than with free combination therapy (adjusted hazard ratio [95% confidence interval]: 0.66 [0.61–0.71]; p < 0.001). Adherence and persistence findings were similar in elderly individuals.
Conclusions
In this real‐world, adult population with T2D in Japan, FRC therapy was associated with improved adherence and persistence versus free combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Endocrinology and Metabolism, Kitasato University School of Medicine, Sagamihara, Japan.
- IQVIA Inc, London, UK.
- Novo Nordisk A/S, Søborg, Denmark.
ORCID-Profile: Takeshi Miyatsuka, Eleanor Davies, Elisabeth de Laguiche, Dorte Vistisen, Can Yin, Atif Adam
Förderung
- Novo Nordisk
Zitieren
APA
Miyatsuka, T., Brash, J., Davies, E., de Laguiche, E., Vistisen, D., Yin, C., & Adam, A. (2026). Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study. Diabetes, Obesity and Metabolism, 28(7), 6291-6300. https://doi.org/10.1111/dom.70812
Vancouver
Miyatsuka T, Brash J, Davies E, de Laguiche E, Vistisen D, Yin C, et al. Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study. Diabetes, Obesity and Metabolism. 2026;28(7):6291-6300. doi:10.1111/dom.70812
BibTeX
@article{Miyatsuka2026,
author = {Miyatsuka, Takeshi and Brash, James and Davies, Eleanor and de Laguiche, Elisabeth and Vistisen, Dorte and Yin, Can and Adam, Atif},
title = {Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {6291--6300},
doi = {10.1111/dom.70812}
}
EUVIMED